Commission Implementing Regulation (EU) 2019/291 of 19 February 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, acrinathrin, azoxystrobin, fluazifop p, fluroxypyr, imazalil, kresoxim-methyl, oxyfluorfen, prochloraz, prohexadione, spiroxamine, tefluthrin and terbuthylazine (Text with EEA relevance.)

• CELEX: Implementing Regulation (EU) 2019/291
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

Part B of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 4, Azoxystrobin, the date is replaced by ‘31 December 2024’;

(2)

in the sixth column, expiration of approval, of row 5, Imazalil, the date is replaced by ‘31 December 2024’;

(3)

in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘31 December 2022’

(4)

in the sixth column, expiration of approval, of row 7, Spiroxamine, the date is replaced by ‘31 December 2023’;

(5)

in the sixth column, expiration of approval, of row 8, Kresoxim-methyl, the date is replaced by ‘31 December 2024’;

(6)

in the sixth column, expiration of approval, of row 9, Fluroxypyr, the date is replaced by ‘31 December 2024’;

(7)

in the sixth column, expiration of approval, of row 10, Tefluthrin, the date is replaced by ‘31 December 2024’;

(8)

in the sixth column, expiration of approval, of row 11, Oxyfluorfen, the date is replaced by ‘31 December 2024’;

(9)

in the sixth column, expiration of approval, of row 12, 1-naphthylacetamide, the date is replaced by ‘31 December 2023’;

(10)

in the sixth column, expiration of approval, of row 13, 1-naphthylacetic acid, the date is replaced by ‘31 December 2023’;

(11)

in the sixth column, expiration of approval, of row 15, Fluazifop P, the date is replaced by ‘31 December 2023’;

(12)

in the sixth column, expiration of approval, of row 16, Terbuthylazine, the date is replaced by ‘31 December 2024’;

(13)

in the sixth column, expiration of approval, of row 19, Acrinathrin, the date is replaced by ‘31 December 2023’;

(14)

in the sixth column, expiration of approval, of row 20, Prochloraz, the date is replaced by ‘31 December 2023’.